Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model

STAT5b as Molecular Target in Pancreatic Cancer—Inhibition of Tumor Growth, Angiogenesis, and Metastases

(2015) Christian Moser et al.   NEOPLASIA

European cancer mortality predictions for the year 2013

(2013) M. Malvezzi et al.   ANNALS OF ONCOLOGY

Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo

(2013) Deniz A. Ucar et al.   Anti-Cancer Agents in Medicinal Chemistry

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma

(2013) A. Avan et al.   CANCER RESEARCH

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

(2013) C Hage et al.   Cell Death & Disease

Postoperative Prognostic Predictors of Pancreatic Ductal Adenocarcinoma: Clinical Analysis and Immunoprofile on Tissue Microarrays

(2012) Joo Kyung Park et al.   ANNALS OF SURGICAL ONCOLOGY

HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast

(2012) Sophie Doublier et al.   BMC CANCER

Current concepts and novel targets in advanced pancreatic cancer

(2012) Patrick Michl et al.   GUT

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer

(2012) Kristen S. Hill et al.   PLoS One

Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?

(2012) Jie-Er Ying   WORLD JOURNAL OF GASTROENTEROLOGY

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target

(2011) Chenwei Li et al.   GASTROENTEROLOGY

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer

(2011) J. Taeger et al.   MOLECULAR CANCER THERAPEUTICS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma

(2010) Guang-Hui Zhu et al.   DIGESTIVE DISEASES AND SCIENCES

Stromal biology and therapy in pancreatic cancer

(2010) A. Neesse et al.   GUT

Advanced pancreatic carcinoma: current treatment and future challenges

(2010) Anastasios Stathis et al.   Nature Reviews Clinical Oncology

Modeling Pancreatic Cancer In Vivo

(2010) Yongzeng Ding et al.   PANCREAS

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice

(2008) Sven A. Lang et al.   HEPATOLOGY

Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes

(2008) S. A. Lang et al.   MOLECULAR CANCER THERAPEUTICS